Carcinoma, Bronchogenic  >>  luminespib (AUY922)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
luminespib (AUY922) / Ligand
NCT01124864 / 2010-020116-11: A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Completed
2
153
US, Canada, Europe, RoW
AUY922
Novartis Pharmaceuticals
Non-small-cell Lung Cancer
08/14
08/14
NCT01922583: AUY922 in Patient With Stage IV NSCLC

Completed
2
31
RoW
AUY922
National Taiwan University Hospital
Non-small Cell Lung Cancer (NSCLC)
02/17
02/17
NCT01854034: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Completed
2
29
US
AUY922
Massachusetts General Hospital
Non Small Cell Lung Cancer
03/17
03/17
NCT01752400: AUY922 for Advanced ALK-positive NSCLC

Completed
2
6
US
AUY922
Massachusetts General Hospital
Non Small Cell Lung Cancer
06/17
11/17

Download Options